Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1]
Hamman L, Rich AR..
Clinical pathologic conference..
Int Clin, (1933), 1 pp. 196-231
[2]
The interstitial pneumonias. En: Simon M, Potchen EJ, Lemay M, editors. Nueva York: Grunne and Stratton;1969. p. 102-41.
[3]
Katzenstein AL.A, Myers JL..
Idiopatic pulmonary fibrosis. Clinical relevance of pathological classification..
Am J Respir Crit Care Med, (1998), 157 pp. 1301-5
[4]
American Thoracic Society / European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias..
Am J Respir Crit Care Med, (2002), 165 pp. 277-304
[5]
Selman M, King TE, Pardo A..
Idiopathic pulmonary fibrosis: prevailing and evolving hypothese about its pathogenesis and implications for therapy..
Ann Intern Med, (2001), 134 pp. 136-51
[6]
Talmadge E, King JR..
Clinical advanctes in the diagnosis and therapy of the interstitial lung diseases..
Am J Respir Crit Care Med, (2005), 172 pp. 268-79
[7]
Sudhakar Pipavath MD, David Godwin J..
Imagining of interstitial lung disease..
Clin Chest Med, (2004), 25 pp. 455-6
[8]
Corticosteroids for idiopathic pulmonary fibrosis (Cochrane review). En: the Cochrane Library. Issue 3. Chichester, UK: Wiley; 2004.
[9]
Raghu G, Brown KK, Bradford WZ, et al..
Placebo-controled trial of interferon Y-1b in patients with idiopathic pulmonary fibrosis..
N Engl J Med, (2004), 350 pp. 125-33
[10]
Bajwa EK, Ayas NT, Schulzer M, et al..
Interferon-Y1b therapic in idiopathic pulmonary fibrosis. A metaanalisis..
Chest, (2005), 128 pp. 203-6
[11]
Douglas WW, Ryu JH, Schroeder DR..
Idiopathic pulmonary fibrosis: impact of oxigen and colchicina, prednisolona or no therapy on survival..
Am J Respir Crit Care Med, (2000), 161 pp. 1172-8
[12]
Douglas WW, Ryu JH, Bjoraker JA, et al..
Colchicine versus prednisone as treatment of usual intersticial pneumonia..
Mayo Clin Proc, (1997), 72 pp. 201-9
[13]
Selman M, Carrillo G, Salas J, et al..
Colchicine, D-penicilamine and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled-clinical trial..
Chest, (1998), 114 pp. 507-12
[14]
Douglas WW, Ryu JH, Swensen SJ, et al..
Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study..
Am J Respir Crit Care Med, (1998), 158 pp. 220-5
[15]
Azuma A, Toshiro N, Tsuboi E, et al..
Double blind, placebo-controlled trial of pirfenidone in patients with idiopatic pulmonary fibrosis..
Am J Respir Crit Care Med, (2005), 171 pp. 1040-7
[16]
Nadrous HF, Ryu JH, Douglas WW, Olson EJ..
Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis..
Chest, (2004), 126 pp. 438-46
[17]
Kubo H, Nakayama K, Masaru Y, et al..
Anticoagulant therapy for idiopathic pulmonary fibrosis. Ces, (2005), 128 pp. 1475-82
[18]
American Thoracic Society..
International guidelines for selection of lung transplant candidates..
Am J Respir Crit Care Med, (1998), 158 pp. 335-9
[19]
Trulock EP..
Lung trasplantation: state of art..
Am J Respir Crit Care Med, (1998), 155 pp. 789-818
[20]
Date H, Tanimoto Y, Goto K, et al..
A new treatment strategy for advanced idiopathic interstitial pneumonia. Living-donor lobar lung transplantation..
Chest, (2005), 128 pp. 1364-70
